Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.552 USD | +9.96% | -6.43% | -60.18% |
May. 08 | Earnings Flash (PIII) P3 HEALTH PARTNERS Reports Q1 Revenue $388.5M, vs. Street Est of $357.2M | MT |
May. 08 | Transcript : P3 Health Partners Inc., Q1 2024 Earnings Call, May 08, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach -100% by 2026.
- The company shows low valuation levels, with an enterprise value at 0.09 times its sales.
- The company appears to be poorly valued given its net asset value.
- The company has a low valuation given the cash flows generated by its activity.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-60.18% | 60.05M | - | ||
+61.12% | 62.59B | B- | ||
-2.20% | 41.18B | B | ||
+44.70% | 40.29B | A | ||
-8.29% | 27.9B | C | ||
+12.66% | 26.21B | B- | ||
-21.82% | 19.09B | B | ||
+5.50% | 13.08B | B+ | ||
+24.94% | 12.26B | B+ | ||
+28.02% | 12.05B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- PIII Stock
- Ratings P3 Health Partners Inc.